Antibiotics player Achaogen sets terms on $65M IPO

The antibiotics developer Achaogen has set its terms for a planned IPO, saying it will sell 5 million shares at $12 to $14 a share. At the midpoint of that range the South San Francisco-based company would raise $65 million. The biotech plans to list under the "AKAO" symbol. Report

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.